Clearpoint Neuro Inc

CLPT

Add to Watchlist

11.640USD

-1.130-8.85%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Clearpoint Neuro Inc's Score

Industry at a Glance

Industry Ranking

84 / 206

Overall Ranking

204 / 4482

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Clearpoint Neuro Inc Highlights

StrengthsRisks

ClearPoint Neuro, Inc. is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. Its flagship product is the ClearPoint Neuro Navigation System. The Company is engaged with healthcare and research centers in North America, Europe, Asia, and South America. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. Its ClearPoint Prism Neuro Laser Therapy System is indicated for use to necrotize or coagulate soft tissue through interstitial irradiation or thermal therapy for neuro applications under 3.0T magnetic resonance imaging (MRI) guidance. The Company also provides solutions for direct CNS delivery of therapeutics in preclinical studies and clinical trials worldwide.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 54.34% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 36.97M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 36.97M.

Fairly Valued

The company’s latest PE is -11.55, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 15.83M shares, increasing 10.52% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 7.32K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.07.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

22.000

Target Price

+72.28%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Clearpoint Neuro Inc is 6.71, ranking 121 out of 206 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 12.13M, representing a year-over-year increase of 42.93%, while its net profit experienced a year-over-year increase of 58.51%.

Score

Industry at a Glance

Previous score

6.71

Change

0



Financials

7.66

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.96

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

6.05

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.79

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.08

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Clearpoint Neuro Inc is 7.11, ranking 121 out of 206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -11.55, which is -56.56% below the recent high of -5.02 and -220.23% above the recent low of -36.98.

Score

Industry at a Glance

Previous score

7.11

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 84/206

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Clearpoint Neuro Inc is 8.00, ranking 66 out of 206 in the Healthcare Equipment & Supplies industry. The average price target is 29.00, with a high of 30.00 and a low of 28.00.

Score

Industry at a Glance

Previous score

8.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Clearpoint Neuro Inc is 7.45, ranking 40 out of 206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 13.43 and the support level at 10.00, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.35

Change

-1.9

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Clearpoint Neuro Inc is 5.00, ranking 110 out of 206 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 52.78%, representing a quarter-over-quarter increase of 23.25%. The largest institutional shareholder is PRFDX, holding a total of 14.22K shares, representing 0.05% of shares outstanding, with 0.84% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

1.81M

+11.33%

MAK Capital One, LLC

1.73M

--

Bigger Capital Funds, LP

1.33M

+3.16%

PTC Therapeutics Inc

894.58K

--

Geode Capital Management, L.L.C.

654.35K

-0.31%

State Street Investment Management (US)

628.06K

+30.13%

Millennium Management LLC

515.38K

+174.43%

StemPoint Capital LP

481.86K

+2793.87%

UBS Financial Services, Inc.

339.81K

-5.79%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Clearpoint Neuro Inc is 3.38, ranking 126 out of 206 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.31. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Clearpoint Neuro Inc’s latest ESG disclosure leads the Healthcare Equipment & Supplies industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Clearpoint Neuro Inc

CLPT

6.67 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Lantheus Holdings Inc

LNTH

8.68 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Anika Therapeutics Inc

ANIK

8.58 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

LivaNova PLC

LIVN

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Thermo Fisher Scientific Inc

TMO

8.35 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Bruker Corp

BRKR

8.23 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment